CN109453249B - Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms - Google Patents
Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms Download PDFInfo
- Publication number
- CN109453249B CN109453249B CN201811590819.2A CN201811590819A CN109453249B CN 109453249 B CN109453249 B CN 109453249B CN 201811590819 A CN201811590819 A CN 201811590819A CN 109453249 B CN109453249 B CN 109453249B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- pharmaceutical composition
- schisandra
- roxburgh rose
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 title abstract description 14
- 206010072268 Drug-induced liver injury Diseases 0.000 title abstract description 14
- 239000002552 dosage form Substances 0.000 title abstract description 7
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 38
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 37
- 241000220317 Rosa Species 0.000 claims abstract description 24
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 17
- 206010067125 Liver injury Diseases 0.000 claims abstract description 16
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 16
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims abstract description 4
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- 238000010298 pulverizing process Methods 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 240000002547 Rosa roxburghii Species 0.000 claims description 11
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 241000736075 Schisandra Species 0.000 claims 7
- 238000000605 extraction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 210000004185 liver Anatomy 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- 230000007882 cirrhosis Effects 0.000 description 8
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- 108090000340 Transaminases Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000014898 transaminase activity proteins Human genes 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- -1 triterpene compounds Chemical class 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- OXVUXGFZHDKYLS-BLIWDXROSA-N Tormentic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-BLIWDXROSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VULLSLYDWNGNKZ-UHFFFAOYSA-N 12319Tetrahydroxyurs-12-en-28-oic acid Natural products OC1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C VULLSLYDWNGNKZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108020005124 DNA Adducts Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010014935 Enzyme abnormality Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930182603 Euscaphic acid Natural products 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OXVUXGFZHDKYLS-UHFFFAOYSA-N Jacarandic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C OXVUXGFZHDKYLS-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001506371 Kadsura Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000973598 Oxyjulis californica Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 244000050053 Rosa multiflora Species 0.000 description 1
- 235000000656 Rosa multiflora Nutrition 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- SOSLMHZOJATCCP-AEIZVZFYSA-N afzelin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O SOSLMHZOJATCCP-AEIZVZFYSA-N 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- OXVUXGFZHDKYLS-QUFHAEKXSA-N euscaphic acid Chemical compound C1[C@@H](O)[C@@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-QUFHAEKXSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- KXMTXZACPVCDMH-UHFFFAOYSA-N methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1CO KXMTXZACPVCDMH-UHFFFAOYSA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for preventing and treating drug-induced liver injury and a preparation method of different dosage forms, wherein the pharmaceutical composition takes roxburgh rose and schisandra chinensis as effective medicinal components and consists of the active medicinal components and acceptable auxiliary additive components in the drugs; the effective medicinal components are calculated by the dry weight of the raw materials of the roxburgh rose and the Chinese magnoliavine fruit, and the mass ratio of the roxburgh rose to the Chinese magnoliavine fruit is 1: 0.1-10. The fructus Rosae Normalis and fructus Schisandrae chinensis can be mixed at a certain proportion to make into tablet, capsule, powder, etc. The pharmaceutical composition has remarkable prevention and treatment effects on drug-induced liver injury, especially alcoholic liver injury, and can also remarkably resist the side effect of schisandra chinensis on increasing liver index.
Description
Technical Field
The invention relates to a pharmaceutical composition for preventing and treating drug-induced liver injury and a preparation method of different dosage forms, in particular to the pharmaceutical composition which enhances the liver protection effect by the combined use of roxburgh rose and schisandra chinensis and simultaneously remarkably resists the side effect of schisandra chinensis on increasing the liver index.
Background
The medicinal liver injury (DILI) refers to the diseases of hepatic cell injury necrosis, liver enzyme abnormality and related clinical manifestations induced by various chemical drugs, biological drugs, Chinese herbal medicines and preparations, health products, dietary supplements and metabolites thereof, and the like. The clinical symptoms mainly comprise digestive tract symptoms such as jaundice, aversion to oil, nausea and the like, and some patients can have anaphylactic reactions such as fever, rash and the like; the biochemical index is mainly changed by the increase of transaminase and bilirubin level. The action mechanism is complex and various, and at present, no drug has the effect of preventing and treating all drug-induced liver injuries. Among them, alcoholic liver injury is the most attractive.
Alcoholic liver disease (alcoholic liver disease) refers to a liver disease caused by excessive ethanol intake for a long time, and the initial stage of the disease generally shows alcoholic fatty liver, and then can develop into alcoholic hepatitis, alcoholic liver fibrosis and alcoholic cirrhosis, and can cause extensive hepatocyte necrosis and liver failure when severe alcoholism occurs. The liver cirrhosis caused by the alcoholic liver damage finally needs a long process, and a clinician needs to take active prevention and treatment measures at the reversible stage of alcoholic liver patients, so that the occurrence and development of the liver cirrhosis are reduced.
Alcoholic cirrhosis constitutes an increasing proportion of the causes of cirrhosis. The analysis of the etiology composition and the change trend of liver cirrhosis patients in northern China in 2002-2010 shows that the alcoholic liver cirrhosis is increased from 3% to 7.7%. In developed regions such as north america and europe, alcoholic liver disease is the leading cause of cirrhosis. In 2010, the number of people who die of alcoholic liver diseases is about 493300, the number of people who have diseases caused by alcohol is about 1450000, and the alcoholic cirrhosis accounts for 47.9% of patients who die of cirrhosis. Korean research on the decade survey between 2000 and 2010 has shown that the rate of cirrhosis in alcoholic liver disease rises from 6.3% to 78.1%. In the united states, cirrhosis was located at the 12 th cause of death in the population in 2002, with a mortality rate that fluctuated at the same level since 1973, with approximately 27794 deaths per year. More than 43.6% of the causes of cirrhosis death are alcohol-related and account for 60.2% of younger cirrhosis people (age 35-45). In 2009 alone, the number of deaths from cirrhosis in the united states reached 31522, 48.2% of which were associated with alcohol, with an socio-economic burden of nearly $ 223.5 million per year due to alcoholic liver disease.
The mechanism of alcohol-induced liver damage is mainly characterized by the following aspects. Ethanol and metabolite toxic effects: early researches show that in the process of generating acetaldehyde by oxidizing ethanol, the ratio of liver NADH/NAD is increased, and NADH can promote the synthesis of fatty acid and inhibit the fatty acid from being oxidized to cause liver steatosis. Meanwhile, the generation of oxygen free radicals is increased, the consumption of antioxidants is increased, the generation of oxidative stress is induced, the respiratory function of cells and the generation of ATP are influenced, and the necrosis or the apoptosis of liver cells is caused. NADH can react with Reactive Oxygen Species (ROS) to cause a cascade inflammatory reaction, releasing more inflammatory factors to damage liver cells. Recent studies have found that ethanol regulates transcription factors associated with fat metabolism, and activation of these transcription factors can promote fat synthesis and inhibit lipolysis. In addition, acetaldehyde can be covalently bound to various proteins in the body to produce acetaldehyde-protein adduct (APA) and DNA adduct, which affect protein function and cause damage to hepatocytes by enzyme inactivation, DNA repair protein dysfunction, lipid peroxidation, and mitochondrial destruction. The acetaldehyde protein adduct is mainly positioned around the central vein, and the liver cells at the position are obviously damaged, so that the collagen synthesis is further stimulated, and the alcoholic liver fibrosis is caused. In addition, alcoholic liver injury is closely related to factors such as endotoxin and abnormal nutrient components.
At present, there is no particularly effective method for preventing and treating alcoholic liver injury, and although abstinence is the best method for preventing and treating alcoholic liver injury, the number of people who drink alcohol and the proportion thereof are increasing year by year due to the increase of social pressure: in recent years, the yield and consumption of alcohol in China tend to increase. Survey data show that the liquor yield in China is 711.3 ten thousand tons in 1984, the yield is increased to 3069.87 ten thousand tons in 2001, and the yield is increased by more than 4 times in nearly 20 years. From the 80 s to the 90 s of the 20 th century, the proportion of alcoholics in the general population rose from 0.21% to 14.3%. Epidemiological investigation and research of part of provinces and cities in China at the beginning of the 21 st century show that the population who drink alcohol is increased to 26.98-43.4%.
Rosa roxburghii Tratt (Rosa roxburghii Tratt), also known as Senchu, Fangji fruit, reeling silk flower, belongs to perennial deciduous shrub of Rosa in Rosaceae, and mainly grows in Guizhou, Sichuan, Yunnan and other places in China.
The roxburgh rose has higher edible value and medicinal value, and modern researches show that fresh roxburgh rose fruits contain abundant substances such as vitamins, polyphenol, flavone, organic acid, polysaccharide, amino acid, trace elements and the like. The fructus Rosae Normalis contains flavonoids up to 0.8%, and its aglycones are myricetin, quercetin and kaempferin; the triterpene compounds mainly comprise roxburgh rose glycoside, pentacyclic triterpene ester glycoside, Euscaphic acid, tormentic acid, roxburgh rose glycoside, and multiflora rose glycoside. The organic acid contained in fructus Rosae Normalis is mainly malic acid, lactic acid, tartaric acid, citric acid, oxalic acid and succinic acid; also contains linoleic acid, linolenic acid, oleic acid, palmitic acid and stearic acid; it also contains superoxide dismutase (SOD) and 18 amino acids, wherein SOD exists mainly in the form of Mn-SOD.
Modern pharmacological research shows that the roxburgh rose has the effects of regulating the immune function of an organism, delaying senility, resisting oxidation, protecting the liver and the like.
Fructus Schisandrae chinensis is dried mature fruit of Schisandra chinensis (Turcz.) Baill. of Magnoliaceae, and is known as "Schisandra chinensis"; it is a commonly used Chinese medicine, and its application history is long, and it is recorded in Shen nong's herbal Jing; the Chinese medicinal herbs are superior in taste, sour and warm in nature, and enter lung, heart and kidney meridians; has the effects of astringing, arresting discharge, benefiting qi, promoting fluid production, invigorating kidney, calming heart, etc.; it can be used for treating chronic cough, asthma, nocturnal emission, enuresis, chronic diarrhea, spontaneous perspiration, night sweat, thirst due to body fluid consumption, palpitation, and insomnia. The schisandra fruit mainly contains lignan compounds accounting for 2-8%, and also contains various components such as volatile oil, polysaccharides, organic acids, fatty acids, proteins and the like. The quality of the Chinese magnoliavine fruit is slightly inferior to that of the northern schisandra fruit.
Modern pharmacological research shows that the schisandra chinensis and the active substances thereof have better effects of resisting oxidation, resisting fatigue, detoxifying, protecting the liver, tranquilizing, hypnotizing and protecting the cardiovascular system.
Although the roxburgh rose has the effect of protecting the liver, the curative effect is weaker; although the liver-protecting effect of schisandra chinensis is stronger than that of rosa roxburghii tratt, schisandra chinensis has the side effect of causing the liver tissue to be remarkably increased.
Disclosure of Invention
In order to obtain a medicine with strong liver protection effect and no side effect of liver tissue enlargement, the invention provides a pharmaceutical composition for preventing and treating drug-induced liver injury and preparation methods of different dosage forms.
The specific technical scheme of the pharmaceutical composition for preventing and treating the drug-induced liver injury is as follows:
a pharmaceutical composition for preventing and treating drug induced hepatic injury comprises fructus Rosae Normalis and fructus Schisandrae as effective medicinal components, and pharmaceutically acceptable auxiliary additive components; the effective medicinal components are calculated by the dry weight of the raw materials of the roxburgh rose and the Chinese magnoliavine fruit, and the mass ratio of the roxburgh rose to the Chinese magnoliavine fruit is 1: 0.1-10.
The effective components of fructus Schisandrae can be obtained by various methods, such as directly using fructus Schisandrae powder as medicine, or extracting fructus Schisandrae with 0-100% water, ethanol water solution or ethanol to obtain fructus Schisandrae extract, and adding fructus Schisandrae extract into medicine.
The fructus Schisandrae chinensis in the effective medicinal components is fructus Schisandrae chinensis or fructus Schisandrae Sphenantherae. The schisandra fruit is usually the northern schisandra fruit, and the quality of the schisandra fruit is better than that of the southern schisandra fruit, and the effective components are more.
The active ingredients of the rosa roxburghii tratt can also be obtained in various ways, such as:
the first method is as follows: the fructus Rosae Normalis in the effective medicinal components is extract obtained by extracting with 0-100% water, ethanol water solution or ethanol.
The second method comprises the following steps: the fructus Rosae Normalis in the effective medicinal components is fructus Rosae Normalis powder obtained by drying and pulverizing fructus Rosae Normalis.
The third method comprises the following steps: the fructus Rosae Normalis in the effective medicinal components is squeezed from fresh fructus Rosae Normalis to obtain juice, or the juice is concentrated and dried to obtain the final product.
The pharmaceutical composition of the invention can be prepared into oral pharmaceutical preparations including common dosage forms such as tablets, dripping pills, capsules, pellets and the like by the pharmaceutical ingredients with drug effect and corresponding auxiliary additives acceptable in the medicaments, such as disintegrating agents, excipients, lubricants, binders, fillers and the like according to the use requirements in the conventional mode.
The invention provides a preparation method of different drug formulations of a drug composition for preventing and treating drug-induced liver injury, which comprises the following specific contents:
the preparation method of the pharmaceutical composition capsule for preventing and treating the drug-induced liver injury comprises the following steps: drying fresh fructus Rosae Normalis, and pulverizing; reflux-extracting fructus Schisandrae with ethanol water solution, recovering extractive solution, and removing ethanol to obtain fructus Schisandrae ethanol extract; adding fructus Rosae Normalis powder into fructus Schisandrae chinensis ethanol extract, mixing, drying, pulverizing, and making into capsule; the dry weight mass ratio of the roxburgh rose powder to the schisandra chinensis is 1: 0.1-10.
In the above preparation method, preferably, the dry weight mass ratio of the roxburgh rose powder to the schisandra chinensis is more than 1; the ethanol water solution is ethanol water solution with ethanol volume fraction of 70%.
The preparation method of the pharmaceutical composition tablet for preventing and treating the drug-induced liver injury comprises the following steps: drying fresh fructus Rosae Normalis, and pulverizing; decocting fructus Schisandrae Sphenantherae with water, removing water decoction, drying the residue, pulverizing, extracting with ethanol water solution under reflux, recovering extractive solution and removing ethanol, standing or centrifuging the water solution, collecting fructus Schisandrae Sphenantherae precipitate, adding fructus Rosae Normalis powder, mixing, drying, pulverizing, and making into tablet; the mass ratio of the roxburgh rose powder to the schisandra chinensis is 1: 0.1-10.
In the above preparation method, preferably, the dry weight mass ratio of the roxburgh rose powder to the schisandra chinensis is less than or equal to 1; the ethanol water solution is ethanol water solution with ethanol volume fraction of 70%.
70% ethanol can extract more effective components from fructus Rosae Normalis or fructus Schisandrae chinensis.
The research of the project group finds that the effect of singly using the roxburgh rose to prevent and treat the drug-induced liver injury is weak, and the expected effect under the ideal dosage is difficult to achieve. The schisandra chinensis has a good prevention and treatment effect on the drug-induced liver injury, but the schisandra chinensis can cause the remarkable enlargement of liver tissues while playing the prevention and treatment effect, and the phenomenon causes new adverse reactions. By combining the schisandra chinensis and the rosa roxburghii tratt, the liver-protecting function can be shown, the side effect of the schisandra chinensis on increasing the liver index can be resisted remarkably, and the application value is good.
Compared with the prior art, the invention has at least the following beneficial effects: the invention provides a pharmaceutical composition with remarkable prevention and treatment effects on drug-induced liver injury, in particular alcoholic liver injury, and meanwhile, the pharmaceutical composition can remarkably resist the side effect of increasing liver index of schisandra chinensis.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Preparation examples of different dosage forms of pharmaceutical composition
Example 1
Taking dried fructus Schisandrae chinensis and fructus Rosae Normalis according to a dry weight ratio of 10:1, pulverizing, sieving with 100 mesh sieve, packaging, and making into powder.
Example 2
According to the following steps: 10, pulverizing dried fructus Rosae Normalis and fructus Schisandrae chinensis, adding 70% ethanol 8 times the amount of the pulverized fructus Rosae Normalis and fructus Schisandrae chinensis, soaking overnight, heating and reflux-extracting for 3 times, mixing filtrates, recovering ethanol, concentrating, drying, adding excipient such as dextrin, and tabletting to obtain 0.5g tablet.
Example 3
According to the following steps: 5 taking dried roxburgh rose and Chinese magnoliavine fruit according to the proportion, and crushing the roxburgh rose into fine powder for later use. Reflux-extracting fructus Schisandrae with 6 times of 70% ethanol for 3 times, recovering solvent to obtain fructus Schisandrae extract, adding the above fructus Rosae Normalis fine powder, mixing, drying, pulverizing, and making into capsule.
Example 4
According to the following steps: 1, taking dried roxburgh rose and kadsura longepedunculata, and crushing the roxburgh rose into fine powder for later use. Decocting fructus Schisandrae Sphenantherae with 8 times of water for 1 time, removing water decoction, drying the residue, pulverizing, extracting with 10 times of 70% ethanol under reflux for 2 times, recovering ethanol, centrifuging the aqueous solution, collecting fructus Schisandrae Sphenantherae precipitate, adding the above fructus Rosae Normalis fine powder, mixing, drying, pulverizing, and making into tablet.
Second, study of the Effect of the drugs of the examples on the liver injury model
1 test Material
1.1 test drugs
Bicyclol sheets: the national standard of medicine H20040467, 25 mg/tablet, lot number 090307, is produced by Beijing collaborating pharmaceutical factory. The suspension is prepared with 0.5CMC to the required concentration before use.
1.2 test animals
Kunming mouse, SPF grade, production certificate number SCXK (Sichuan 2018-19), provided by the Experimental animals center of the academy of traditional Chinese medicine and sciences of Sichuan province.
1.3 test apparatus
An electronic balance: shimadzu EB-3200, produced in Japan.
2 methods and results
2.1 Effect on Alcoholic liver injury mice
Male mice with the weight of 18-22g are taken, randomly grouped, and respectively administered by intragastric administration 1 time a day for 7 days. On the 4 th day of administration, the groups except the normal control group were each gavaged with 0.1ml/10g of 50% ethanol in a weight-average manner in mice for 4 times. After 24h after the last administration and 16h after fasting without water prohibition, blood is taken to measure ALT and AST serum, the animal is killed, the liver is taken to weigh the wet weight, and the organ index is calculated. The results are shown in Table 1.
TABLE 1 Effect of the examples on alcoholic liver injury mice (x. + -.s)
Comparison with model groups:*P<0.05,**P<0.01,***P<0.001.
comparison with the group of five flavors:△P<0.05,△△P<0.01,△△△P<0.001.
as can be seen from table 1, the serum transaminase and liver index of the mice significantly increased after 4 days of continuous alcohol administration, which is statistically different from that of the control group. The schisandra chinensis can obviously reduce the serum glutamic-pyruvic transaminase of mice with alcoholic liver when used alone, but can obviously increase the liver index of the mice with alcoholic liver, and compared with a model group, the difference has statistical significance. The roxburgh rose is used alone, has a tendency of reducing transaminase activity, but has weak effect, has no obvious influence on liver index, and has no statistical difference compared with a model group. When the roxburgh rose and the schisandra chinensis are used together, transaminase of an alcoholic liver mouse can be reduced remarkably, liver index of an alcoholic liver injury mouse is reduced, and compared with a model group, the difference has statistical significance, and compared with a single schisandra chinensis group, the difference has statistical significance. The other embodiments also have similar effects.
2.2 protective action on mouse acute liver injury caused by carbon tetrachloride
Taking male mice with weight of 18-22g, randomly grouping, respectively intragastrically administering twice a day, continuously 5 times, 1 hr after the last administration, and intraperitoneally injecting CCl4After 10uL/kg and fasting for 16 hours without water prohibition, blood is taken for measuring ALT and AST activities of the serum. The results are detailed in table 2.
TABLE 2 Effect on carbon tetrachloride induced acute liver injury in mice (x + -s)
Comparison with model groups:*P<0.05,**P<0.01,***P<0.001.
as can be seen from Table 2, carbon tetrachloride caused a significant increase in serum transaminase activity in mice, which was statistically different from the control group. The examples can significantly reduce serum transaminase of mice with carbon tetrachloride, and have statistical differences compared with a model group.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (10)
1. The application of a pharmaceutical composition which is composed of the rosa roxburghii tratt and the schisandra chinensis as effective medicinal components and auxiliary additive components acceptable in the medicine in preparing the medicine for preventing and treating the alcoholic liver injury, wherein the mass ratio of the rosa roxburghii tratt to the schisandra chinensis is 1: 0.1-10.
2. The use according to claim 1, wherein the schisandra fruit of the effective pharmaceutical ingredient is an extract of schisandra fruit obtained by extraction with water, aqueous ethanol solution or ethanol with a volume fraction of ethanol of 0-100%.
3. The use according to claim 1, wherein the schisandra fruit in the effective pharmaceutical ingredient is schisandra fruit or schisandra fruit.
4. The use according to claim 1, wherein the Rosa roxburghii Tratt is an extract obtained by extracting with water, ethanol water solution or ethanol with ethanol volume fraction of 0-100%.
5. The use according to claim 1, wherein the Rosa roxburghii Tratt in the effective pharmaceutical ingredient is powder of Rosa roxburghii Tratt obtained by drying and pulverizing Rosa roxburghii Tratt.
6. The use of claim 1, wherein the fructus Rosae Normalis is squeezed from fresh fructus Rosae Normalis to obtain juice, or the juice is concentrated and dried to obtain the final product.
7. The use according to claim 1, characterized in that the preparation method of the pharmaceutical composition capsule comprises the following steps: drying fresh fructus Rosae Normalis, and pulverizing; reflux-extracting fructus Schisandrae with ethanol water solution, recovering extractive solution, and removing ethanol to obtain fructus Schisandrae ethanol extract; adding fructus Rosae Normalis powder into fructus Schisandrae chinensis ethanol extract, mixing, drying, pulverizing, and making into capsule; the dry weight mass ratio of the roxburgh rose powder to the schisandra chinensis is 1: 0.1-10.
8. Use according to claim 7, characterized in that the dry weight to mass ratio of the roxburgh rose powder and the schisandra fruit is greater than 1; the ethanol water solution is ethanol water solution with ethanol volume fraction of 70%.
9. Use according to claim 1, characterized in that the process for the preparation of tablets of the pharmaceutical composition comprises the following steps: drying fresh fructus Rosae Normalis, and pulverizing; decocting fructus Schisandrae Sphenantherae with water, removing water decoction, drying the residue, pulverizing, extracting with ethanol water solution under reflux, recovering extractive solution and removing ethanol, standing or centrifuging the water solution, collecting fructus Schisandrae Sphenantherae precipitate, adding fructus Rosae Normalis powder, mixing, drying, pulverizing, and making into tablet; the mass ratio of the roxburgh rose powder to the schisandra chinensis is 1: 0.1-10.
10. Use according to claim 9, characterized in that the dry weight to mass ratio of the roxburgh rose powder and the schisandra fruit is less than or equal to 1; the ethanol water solution is ethanol water solution with ethanol volume fraction of 70%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811590819.2A CN109453249B (en) | 2018-12-20 | 2018-12-20 | Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811590819.2A CN109453249B (en) | 2018-12-20 | 2018-12-20 | Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109453249A CN109453249A (en) | 2019-03-12 |
| CN109453249B true CN109453249B (en) | 2021-06-22 |
Family
ID=65614735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811590819.2A Active CN109453249B (en) | 2018-12-20 | 2018-12-20 | Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109453249B (en) |
-
2018
- 2018-12-20 CN CN201811590819.2A patent/CN109453249B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 吴德智等.响应曲面法优化五味子刺梨复合功能果酱的工艺研究.《中国调味品》.2017,第42卷(第7期),第106-112页. * |
| 响应曲面法优化五味子刺梨复合功能果酱的工艺研究;吴德智等;《中国调味品》;20170731;第42卷(第7期);第106-112页，尤其是第112页结论 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109453249A (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
| CN102091315A (en) | Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| KR101347826B1 (en) | A composition comprising the combined extract of ISRK for preventing and treating diabetes mellitus and diabetic complication | |
| CN105942498A (en) | Functional nutritional food compounds with diabetes-treating effects and preparation methods thereof | |
| KR20130128755A (en) | Composition comprising an extract of combined crude drug for preventing and treating hangover or liver disease | |
| CN106135891A (en) | A kind of health food to alcoholic liver injury with defencive function | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| KR101826737B1 (en) | A composition containing herbs extract, and manufacturing method of the same | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| CN101243882A (en) | Health food with function of reducing blood fat and its preparation | |
| Wei et al. | Phytochemistry and pharmacology of Armeniacae semen Amarum: A review | |
| CN103155985A (en) | Rhizoma polygonati nutrition powder and preparation method thereof | |
| CN109480238A (en) | A kind of food with liver protecting | |
| CN101172155A (en) | Novel dosage forms of pulse-activating gallbladder warming soup and method of preparing the same | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN109453249B (en) | Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms | |
| KR100543556B1 (en) | Composition containing Alpiniae Semen and Pueraria Flower | |
| KR20100133079A (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
| CN101822705A (en) | Total platycodin and application of monomer platycodin D in antialcoholic drugs | |
| KR102282839B1 (en) | Composition for relieving or improving hangover | |
| KR100685472B1 (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome | |
| CN110959721A (en) | Solid beverage of edible herbal tea | |
| CN104906243A (en) | Traditional Chinese medicine compound with liver protection function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |